Barclays Upgrades Sagimet Biosciences to Overweight, Raises Price Target to $18

Benzinga Newsdesk www.benzinga.com Positive 92.7%

Neg 0% Neu 0% Pos 92.7%

Barclays analyst Eliana Merle upgrades Sagimet Biosciences (NASDAQ:SGMT) from Equal-Weight to Overweight and raises the price target from $8 to $18.